Following its acquisition of Swedish nuclear medicine firm Hermes Medical Solutions in April 2016, private equity partnership Segulah V said it will continue to increase its investment in the firm, both in development and operations, to ensure its success in molecular imaging.
Segula V's investment strategy for global growth continues according to the plan that was developed at acquisition, Hermes said, adding that the investment helps it create sustainable long-term value as it continues to build relationships.
Hermes develops software for integrating, visualizing, processing, and archiving imaging data from different modalities and devices in molecular imaging and radiology.
